Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
β-sheet protein aggregates are assemblies of misfolded proteins characterized by an extensive β-sheet structure, where β-strands run perpendicular to the fiber axis and are stabilized by interstrand hydrogen bonds. These aggregates are insoluble, highly stable, and resistant to degradation, forming fibrillar deposits known as amyloid. Formation typically occurs due to improper protein folding, mutations, or chemical modifications, and is associated with cytotoxicity and cell stress. β-sheet aggregates serve as pathological markers and therapeutic targets in diseases such as Alzheimer's, Parkinson's, and systemic amyloidoses. They are not unique molecular entities but represent a common structural motif in disease-related protein aggregation.
Antibodies/binders that promote clearance of aggregates Small molecules that inhibit aggregation or promote disaggregation Stabilization of native protein conformation to prevent misfolding Inhibition of nucleation/elongation of fibrils
3 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on β-sheet protein aggregate (None in standard usage).